Tirzepatide in Treating Metabolic Disorders

Shulin Wei; Suowen Xu

doi:10.53941/ijddp.2024.100023

Abstract

Type 2 diabetes (T2D) and obesity are chronic diseases associated with high morbidity worldwide, seriously threatening people’s life and health. Tirzepatide, as a novel glucagon-like peptide 1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-targeted agonist, has been proven to be effective in reducing body weight and controlling blood glucose levels in several clinical studies. Therefore, it has been approved by the Food and Drug Administration (FDA) for treating T2D and managing chronic weight in overweight or obese patients, with good therapeutic effects, safety and tolerability. Metabolic dysfunction-associated steatohepatitis (MASH), a metabolic syndrome related to T2D and obesity, is considered an independent risk factor for cardiovascular disease. It can decrease levels of markers associated with MASH and liver fibrosis and even led to the MASH resolution with no fibrosis worsening in treating T2D patients, without increasing the risk of cardiovascular events. The available evidence suggests that it may have potential therapeutic effects on MASH. This review presents a summary of recent preclinical studies and clinical trials on the application of tirzepatide to treat diabetes, obesity, MASH, cardiovascular disease, and kidney disease and reveals the promising prospect of using tirzepatide as a magic bullet in treating metabolic disorders.

References

1.
Moura, F.A.; Scirica, B.M.; Ruff, C.T. Tirzepatide for diabetes: On track to SURPASS current therapy. Nat. Med.2022, 28, 450–451.
2.
Gasbjerg, L.S.; Helsted, M.M.; Hartmann, B.; et al. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes 2019, 68, 906–917.
3.
Gabery, S.; Salinas, C.G.; Paulsen, S.J.; et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020, 5, e133429.
4.
Zhang, Q.; Delessa, C.T.; Augustin, R.; et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021, 33, 833–844.e5.
5.
Corrao, S.; Pollicino, C.; Maggio, D.; et al. Tirzepatide against obesity and insulin-resistance: Pathophysiological aspects and clinical evidence. Front. Endocrinol. 2024, 15, 1402583.
6.
Miao, L.; Targher, G.; Byrne, C.D.; et al. Current status and future trends of the global burden of MASLD. Trends Endocrin Met. 2024, 35, 697–707.
7.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 2024, 81, 492–542.
8.
Hartman, M.L.; Sanyal, A.J.; Loomba, R.; et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care 2020, 43, 1352–1355.
9.
Taktaz, F.; Fontanella, R.A.; Scisciola, L.; et al. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: Evidence for the role of tirzepatide. Cardiovasc. Diabetol. 2024, 23, 242.
10.
Krumholz, H.M.; de Lemos, J.A.; Sattar, N.; et al. Tirzepatide and blood pressure reduction: Stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart 2024, 110, 1165–1171.
11.
Chen, L.; Chen, X.; Ruan, B.; et al. Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling. Peptides 2024, 178, 171245.
12.
Ong, K.L.; Stafford, L.K.; McLaughlin, S.A.; et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234.
13.
Regmi, A.; Aihara, E.; Christe, M.E.; et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024, 36, 1534–1549.
14.
Ahrén, B.; Pacini, G. Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice. J. Diabetes Investig. 2021, 12, 675–685.
15.
Pacini, G.; Ahrén, B. The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice. Peptides 2024, 171, 171117.
16.
Frias, J.P.; Nauck, M.A.; Van, J.; et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018, 392, 2180–2193.
17.
Rosenstock, J.; Wysham, C.; Frías, J.P.; et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. Lancet 2021, 398, 143–155.
18.
Frías, J.P.; Davies, M.J.; Rosenstock, J.; et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 503–515.
19.
Mather, K.J.; Mari, A.; Heise, T.; et al. Effects of Tirzepatide vs Semaglutide on β-cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. J. Clin. Endocrinol. Metab. 2024, 109, 3046–3054.
20.
Del Prato, S.; Kahn, S.E.; Pavo, I.; et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021, 398, 1811–1824.
21.
Gao, L.; Lee, B.W.; Chawla, M.; et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: The SURPASS-AP-Combo trial. Nat. Med. 2023, 29, 1500–1510.
22.
Chuang, M.H.; Chen, J.Y.; Wang, H.Y.; et al. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw. Open 2024, 7, e2427258.
23.
Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023, 35, 414–428.e3.
24.
Liu, L.; Shi, H.; Xie, M.; et al. Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Int. J. Clin. Pharm. 2024, 46, 1268–1280.
25.
Coskun, T.; Sloop, K.W.; Loghin, C.; et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol. Metab. 2018, 18, 3–14.
26.
Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N. Engl. J. Med. 2022, 387, 205–216.
27.
Wadden, T.A.; Chao, A.M.; Machineni, S.; et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nat. Med. 2023, 29, 2909–2918.
28.
Aronne, L.J.; Sattar, N.; Horn, D.B.; et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024, 331, 38–48.
29.
Garvey, W.T.; Frias, J.P.; Jastreboff, A.M.; et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023, 402, 613–626.
30.
Zhao, L.; Cheng, Z.; Lu, Y.; et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The Surmount-CN Randomized Clinical Trial. JAMA 2024, 332, 551–560.
31.
Rodriguez, P.J.; Goodwin Cartwright, B.M.; Gratzl, S.; et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern. Med. 2024, 184, 1056–1064.
32.
Malhotra, A.; Grunstein, R.R.; Fietze, I.; et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N. Engl. J. Med. 2024, 391, 1193–1205.
33.
Ledford, H. First US drug approved for a liver disease surging around the world. Nature 2024, https://doi.org/10.1038/d41586-024-00747-9.
34.
Wei, S.; Wang, L.; Evans, P.C.; et al. NAFLD and NASH: Etiology, targets and emerging therapies. Drug Discov. Today 2024, 29, 103910.
35.
Jeong, B.K.; Choi, W.I.; Choi, W.; et al. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nat. Commun. 2024, 15, 6506.
36.
Loomba, R.; Hartman, M.L.; Lawitz, E.J.; et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N. Engl. J. Med. 2024, 391, 299–310.
37.
Gastaldelli, A.; Cusi, K.; Fernández Landó, L.; et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022, 10, 393–406.
38.
de Lemos, J.A.; Linetzky, B.; le Roux, C.W.; et al. Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥ 27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension 2024, 81, e41–e43.
39.
Nicholls, S.J.; Bhatt, D.L.; Buse, J.B.; et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am. Heart J. 2024, 267, 1–11.
40.
Heerspink, H.J.L.; Sattar, N.; Pavo, I.; et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022, 10, 774–785.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us